Abstract

**Objective**: To determine the prevalence of hemorrhagic gastro-intestinal (GI) disease developing in dogs and cats admitted for management of non-GI disease in veterinary intensive care units (ICUs).

**Design**: Retrospective study of animals presented between October 2012 and July 2013.

**Setting**: Three ICUs located in veterinary teaching hospitals in the United Kingdom.

**Animals**: Dogs (n=272) and cats (n=94) were consecutively enrolled from three ICUs if they were hospitalized in the unit for at least twenty-four hours. Cases were excluded if they had hemorrhagic GI disease in the forty-eight hour period before presentation or in the twenty-four hour period after admission. Cases were also excluded if they suffered skull fracture, epistaxis or hemoptysis, if they underwent surgical procedures of the GI or upper respiratory tracts, or if they were presented for management of GI disease.

**Measurements and Main Results**: Hemorrhagic GI disease was observed in dogs at all three units, but at different rates (Center 1: 10.3%, Center 2: 4.8%, Center 3: 2.2%). Hemorrhagic GI disease was not observed in cats at any of the participating centers. Construction of a multivariable logistic regression model revealed that serum albumin concentration, administration of prophylactic gastro-protectant drugs and institution were significantly associated with the development of hemorrhagic GI disease in dogs. Development of hemorrhagic GI disease and placement of a feeding tube were significantly associated with mortality during the period of hospitalization in dogs. Thirty-seven (13.6%) dogs and 12 (12.8%) cats died or were euthanized while hospitalized, with a higher mortality rate (42.1%) in dogs with hemorrhagic GI disease.
Conclusions: Hemorrhagic GI disease does develop in dogs hospitalized for management of non-GI disease, but this phenomenon was not observed in cats. Development of hemorrhagic GI disease appeared to have a significant impact on survival in veterinary ICUs.

Keywords: Stress-related mucosal disease, stress ulcer prophylaxis, omeprazole, enteral feeding

Introduction

In human medicine, stress-related mucosal disease (SRMD) refers to the development of erosive lesions of the stomach and intestines in patients admitted to ICUs for management of severe illness\(^1\). The term covers a spectrum of disease, from superficial mucosal injury detectable only by gastroduodenoscopy to severe ulceration that results in clinically important hemorrhage. Overt clinical bleeding due to SRMD was reported to occur in approximately 4% of humans admitted to a group of ICUs in Canada\(^2\), and development of this disease significantly increased the risk of death during the period of hospitalization.

Impaired perfusion of the gastric mucosal barrier (GMB) is the proximate cause of SRMD, but development of the disease is reflective of systemic changes in hemodynamic status and inflammatory cascade\(^3\). Splanchnic hypoperfusion caused by sympathetic stimulation or hypovolemia is likely to be an important factor in the development of SRMD but it may be difficult to detect in patients that appear to have adequate macrohemodynamic markers of systemic perfusion\(^4\). Reduced splanchnic blood flow also increases the risk of reperfusion injury caused by oxygen free radicals if blood flow is restored after appropriate resuscitation\(^5\). Local or systemic production of pro-inflammatory cytokines such as tumour necrosis factor alpha and interleukins 1 and 8 causes further alterations in perfusion of the gastric mucosa and disrupts the production of mucus and bicarbonate\(^6\), which are required for neutralization of gastric
acid. If the GMB is sufficiently disrupted by these changes, gastric acid may cause direct damage to the mucosa, and this process can progress to cause substantial ulceration and hemorrhage.

Several factors have been identified in human patients that increase the risk of development of SRMD², particularly respiratory failure necessitating mechanical ventilation and coagulopathy. Administration of prophylactic gastro-protectant medications reduces the risk of SRMD², but this may be associated with development of other complications, such as aspiration pneumonia, because increased gastric pH permits bacterial colonization of the stomach¹³.

Hemorrhagic GI disease has not been described specifically in veterinary ICUs, but two studies identified subclinical gastric erosions in dogs that underwent decompressive surgery for intervertebral disc disease, some of which also received glucocorticoids⁷,⁸. These lesions did not appear to be responsive to administration of gastro-protectant medications. The pathogenesis of gastric ulceration in Alaskan sled dogs at the Iditarod race may also share some features with that of SRMD in people. Strenuous exercise in these dogs resulted in increased gastric permeability and increased frequency of gastric lesions observed by endoscopy⁹,¹⁰. The authors of this study speculated that these changes could occur due to increased circulating glucocorticoid concentrations or diversion of cardiac output to skeletal muscle for exercise. Two further studies described development of gastroduodenal ulceration in critically ill animals in association with various underlying causes, including hepatic disease, pancreatitis, hypoadrenocorticism, and administration of non-steroidal anti-inflammatory drugs (NSAIDs)¹¹,¹².

The primary aim of this study was to determine the proportion of animals that developed overt hemorrhagic GI disease in veterinary ICU patients. It was hypothesized that this would occur at similar rates to those reported in human ICUs, and that dogs would develop the disease more frequently than cats based on previous evidence suggesting that the GI tract is not the shock organ of cats. Secondary aims
were to investigate risk factors for the development of hemorrhagic GI disease, and to determine whether
development of these signs was associated with mortality during the period of hospitalization.

Materials and Method

Study design  A retrospective multi-center survey was conducted at three intensive care units
(Centers 1, 2 and 3) located in teaching hospitals in the UK. These units accept referral cases from
veterinarians in general practice and from other specialist services within the same institutions. Case
management in each unit is supervised by board certified clinicians in emergency and critical care,
internal medicine, surgery or neurology. Entry and egress of patients from the ICUs and use of any drugs,
including gastro-protectant medications, were at the discretion of the attending clinician.

All cases presenting consecutively to the ICUs were considered eligible for enrolment during the
period of the study if they were hospitalized for at least twenty-four hours. Cases were excluded if they
had a history of hemorrhagic GI disease in the forty-eight hours prior to hospitalization or if they
developed signs within the first twenty-four hours after admission. Cases were also excluded if they
underwent surgical procedures involving the GI or upper respiratory tracts, if they presented with or
developed epistaxis or hemoptysis, if they presented for management of GI disease, or if they had
sustained one or more skull fractures. Cases were not excluded if they received gastro-protectant drugs,
NSAIDs, glucocorticoids or anticoagulants prior to admission or during hospitalization, nor if they were
diagnosed with diseases that may cause secondary GI signs, such as hypoadrenocorticism.

Data collection:  A single entry form was produced for each case enrolled in the study
(Supplementary Data 1), and this was completed by a veterinarian after the patient was discharged from
the ICU. The veterinarian completing the enrolment form did not necessarily have primary responsibility
for the case. The following data were collected from the medical records of each case: signalment,
presenting problem and problems identified after initial consultation, concurrent diseases and medications, clinical examination findings, GI signs observed while hospitalized, and results of complete blood cell count, serum biochemistry and coagulation profiles performed on admission. Types of feeding tube placed in individual patients were recorded, as were the types and doses of any gastro-protectant, NSAID, glucocorticoid or antithrombotic medications administered in the ICU. The length of hospitalization, the nature of any surgical procedures conducted immediately before or during the period of ICU hospitalization, and mortality or euthanasia while hospitalized were also noted.

SRMD was defined as hemorrhagic GI disease manifesting as hematemesis, melena or hematochezia or as mucosal erosions and hemorrhage observed during GI endoscopy. Dogs were diagnosed with systemic inflammatory response syndrome (SIRS) if they fulfilled two or more of the following four conditions: rectal temperature <37.2°C or >39.2°C, heart rate >140 beats per minute, respiratory rate >30 breaths per minute, or total white blood cell count <6x10⁹/l (6,000/µl) or >19x10⁹/l (19,000/µl)¹⁵.

**Statistical analysis:** All statistical analyses were conducted using a commercial software program. Shapiro-Wilk tests and visual assessments of histograms were used to determine whether variables were parametrically distributed. Parametric and non-parametric variables were compared using Student’s *t* tests and Mann-Whitney *U* tests, respectively. Categorical data were compared using Fisher’s exact tests or Chi squared tests. Confidence intervals, where stated, are at the 95% level.

The proportion of veterinary patients that developed SRMD was determined by dividing the number of cases with hematemesis, melena or hematochezia by the total number of included cases collectively and for each ICU, and 95% confidence intervals were calculated.
Multivariable logistic regression was used to evaluate risk factors for development of SRMD and for mortality during hospitalization. Univariable analyses were first conducted using Mann-Whitney U tests, Chi squared tests or Fisher’s exact tests, and variables with p values <0.2 were retained. These variables were entered together in the multivariable analysis, and a model was fitted using a forward entry method based on calculation of likelihood ratios. A categorical variable describing whether prophylactic gastro-protectant medications were administered was forced into the final model for development of SRMD, and a variable describing whether cases fulfilled the SIRS criteria was forced into the model of mortality as these factors were considered to be of considerable a priori importance for each model based on published evidence\textsuperscript{2,16}. Institute was included as a factor in both models to account for possible differences between centers. Hosmer-Lemeshow tests were performed to assess the adequacy of model fit, and receiver operator characteristic (ROC) curves were produced using probabilities derived from each logistic regression model to determine the predictive capability of each model.

Results

**Study populations:** After removal of duplicate cases and application of exclusion criteria, 272 dogs and 94 cats were included in the study (Figure 1). Of the dogs included, 159 (58.5%) were from Center 1, 21 (7.7%) were from Center 2, and 92 (33.8%) were from Center 3. Of the cats, 67 (71.3%) were from Center 1, 7 (7.4%) were from Center 2, and 20 (21.3%) were from Center 3. **Seventy-one dogs** were intact males, 37 intact females, 82 neutered males and 82 neutered females, whereas 3 cats were intact males, 4 intact females, 51 neutered males and 36 neutered females.

There was no difference in median age between dogs and cats, nor between animals of either species at different centers.
Prevalence of GI disease: The proportion of dogs that developed SRMD was 10.3% (CI: 6.3-15.7) at Center 1, 4.8% (CI: 0.85-22.7) at Center 2 and 2.2% (CI: 0.6-7.7) at Center 3, with a combined proportion of 7.0% (CI: 4.5-10.7). The difference in proportions between centers was not significant (Chi square 5.2, \( p = 0.075 \)). SRMD did not occur in any of the cats observed during this study at any center. Among the dogs that received prophylactic gastro-protectant medications, the proportion that developed SRMD was 16.4% (CI: 8.9-28.3), compared to 4.2% (CI: 2.2-7.8) in dogs that did not receive prophylaxis, and there was a significant difference in these proportions (Chi square 10.3, \( p = 0.001 \)). Rates of development of SRMD during hospitalization in dogs and cats at each center are shown in Table 2.

Of the dogs that developed SRMD (n=19), the most common diagnoses were immune-mediated disease (4), neoplasia (2), trauma (2), and Angiostrongylus vasorum infestation (2). The remaining dogs were diagnosed with pyelonephritis (1), fasciitis (1), traumatic brain injury (1), hepatic disease (1), intervertebral disc protrusion (1), hypoadrenocorticism (1), sudden acute retinal degeneration syndrome (1), sepsis and disseminated intravascular coagulation (1), and intra-abdominal hemorrhage following ovariohysterectomy (1).

Feeding tubes were placed in 27 animals across all centers. Only esophagostomy tubes were placed in cats (n=7), but naso-esophageal (n=12), esophagostomy (n=5) and gastrostomy (n=3) tubes were placed in dogs. The majority of the tubes were placed at Center 1 (n=23), with a smaller number at Center 3 (n=4). Placement of a feeding tube was undertaken at Center 1 after a median period of anorexia of 3 days (IQR: 3-5, range 2-9, n=13). The duration of anorexia could not be determined in 6 dogs, and a naso-esophageal feeding tube was placed in the remaining 4 dogs as a standard preparation for mechanical ventilation.
Evaluation of risk factors for development of SRMD: Univariable analyses revealed that multiple factors were associated with development of SRMD (Table 3). When these variables were entered into the multivariable analysis, decreased serum albumin concentration, institute and administration of prophylactic gastro-protectant medications were retained in the final model. Dogs with SRMD were 4.3 (CI: 1.2-15.5) times more likely to have decreased serum concentrations of albumin, 4.3 (CI: 1.4-13.7) times more likely to have received prophylactic gastro-protectant medications and 10.0 (CI: 1.7-33.3) times less likely to have been hospitalized at Center 3 than those that did not develop SRMD. Performance of the Hosmer-Lemeshow test indicated good model fit (Chi Square 2.2, \( p = 0.826 \)), and the area under the ROC curve constructed using model probabilities was 0.79 (CI: 0.68-0.90)(Supplementary Figure 1A), showing that the model was able to discriminate adequately between cases with and without SRMD. A ROC curve was also generated using individual values for serum albumin concentration (n=201), and the area under the curve was smaller using this model (0.68, CI: 0.52-0.84)(Supplementary Figure 1B). Using a cut-off value of 28.0 g/l (2.8 g/dl), the sensitivity and specificity values for prediction of development of SRMD were 0.67 and 0.62, respectively.

Hospitalization and survival: The median durations of hospitalization and mortality rates for dogs and cats at different centers are shown in Table 2. There was no difference in duration of hospitalization between cats and dogs from all centers, but average length of hospitalization was greater at both Centers 2 (\( p = 0.048 \)) and 3 (\( p < 0.001 \)) compared to Center 1. Thirty-seven (13.6%) dogs and 12 (12.8%) cats died or were euthanized while hospitalized. Mortality rates were similar between centers and species, but the proportion of dogs with SRMD that did not survive to discharge (8/19 dogs, 42.1%) was significantly greater than for dogs that did not develop SRMD (29/252, 11.5%; Chi square 14.0, \( p < 0.001 \)).
Evaluation of risk factors for mortality during hospitalization: Significant associations were detected between several variables and mortality during hospitalization using univariable analysis (Table 4). When these variables were entered into the multivariable analysis, placement of a feeding tube and development of SRMD were associated with mortality. Dogs that died or were euthanized while hospitalized were 13.3 (CI: 4.0-43.5) times more likely to have had a feeding tube placed and 5.1 (CI: 1.6-15.9) times more likely to have developed SRMD than those that were discharged. Fulfilment of the SIRS criteria and institute were forced into the final model, but these variables were not significantly associated with mortality. The model fit was adequate (Hosmer-Lemeshow Chi square 5.7, \( p = 0.338 \)), and generation of a ROC curve using model probabilities yielded an area under the curve of 0.77 (CI: 0.68-0.86) (Supplementary Figure 2).

Naso-esophageal feeding tubes were placed routinely in dogs that were mechanically ventilated. When these animals were excluded from the analysis (n=4), the odds ratio for tube placement decreased to 8.5 (CI: 2.4 – 30.3, \( p = 0.001 \)), while that for development of SRMD did not change considerably (OR: 5.1, CI: 1.6 – 15.9, \( p = 0.006 \)). Model fit parameters were similar to those reported above (data not shown).

Discussion

The results of this study show that hemorrhagic GI disease, defined here as SRMD, does occur in dogs hospitalized in veterinary ICUs, but was not observed in any of the cats that were included. Dogs with SRMD were more likely to have decreased serum concentrations of albumin on presentation, but this parameter had a low sensitivity and specificity for prediction of development of this disease. Affected animals were also more likely to have received prophylactic gastro-protectant medications and less likely to have been hospitalized at Center 3. SRMD and placement of a feeding tube were significantly more likely to occur in dogs that died or were euthanized while hospitalized.
The proportion of dogs that developed SRMD varied considerably between Centers, and dogs at Center 3 were at significantly reduced risk compared to either Center 1 or 2. The cause of this difference is not apparent: SRMD could have developed at similar rates at Centers 2 and 3 as at Center 1 but was not recorded, although the authors consider this scenario to be unlikely as occurrence of all forms of GI disease is considered to be a notable event among nursing staff and attending clinicians at all three centers. The true prevalence of SRMD at Center 2 may also differ from that reported due to the small number of cases observed in this study, as indicated by the wide confidence intervals for this parameter.

Measurable hemorrhage due to stress-related GI injury is reported to occur in approximately 4-6% of affected humans\textsuperscript{2,16}, which is broadly comparable to the proportion of dogs affected with SRMD defined according to this study. In contrast to human intensive care, none of the animals included in this study underwent gastroduodenoscopy, which is a much more sensitive technique for detection of superficial erosions in the acid-secreting sections of the stomach. When this technique was applied in dogs undergoing surgery for management of inter-vertebral disc disease, subclinical lesions were observed in approximately 75% of patients\textsuperscript{7,8}. The animals considered in this study are therefore likely to represent the most severely affected patients in a spectrum of stress-related GI disease, similar to the syndrome of clinically important bleeding in humans with SRMD.

SRMD was not observed in any of the 94 cats that were included in this study, and this finding is consistent with the hypothesis that the GI tract is not a ‘stress organ’ in cats. Previous experimental\textsuperscript{17} and epidemiologic\textsuperscript{18,19} studies indicate that cats are susceptible to pulmonary injury when suffering from systemic inflammation or sepsis, and there are no previous reports suggestive of SRMD in this species. Observation of a greater number of cats in ICUs is likely to be required to determine whether SRMD occurs at lower prevalence than could be detected during this study.
Dogs that developed SRMD were more likely to have decreased serum albumin concentrations at presentation. Albumin is an essential product used in maintaining the GMB, and dogs with decreased albumin concentrations are reported to be at increased risk of dehiscence following incisional biopsy of the small intestine\textsuperscript{20}. It is therefore possible that dogs with hypoalbuminemia are at increased risk of SRMD and other GI signs due to their inability to maintain an effective mucosal wall. Alternatively, the albumin concentration could be decreased in patients that have clinically undetectable GI injury resulting in increased GI permeability and protein-losing enteropathy, prior to the onset or recognition of hemorrhagic GI disease. Investigation of Alaskan sled dogs indicated that increased gastric permeability was an early event in development of erosive gastric disease in this cohort\textsuperscript{10}, suggesting that hypoalbuminemia could be an effect rather than a cause of the GI signs observed. Hypoalbuminemia in this study may also represent a non-specific marker of illness, as serum albumin is a negative acute phase protein. Decreased serum concentrations of albumin have also been identified as negative independent prognostic factors in two studies of dogs admitted to veterinary ICUs\textsuperscript{21,22}.

With a cut off value of 28.0 g/l (2.8 g/dl, the lower limit of the reference range in use at Center 1), serum albumin concentration had a poor sensitivity and specificity for prediction of the development of SRMD, limiting the usefulness of this parameter in guiding the use of prophylactic interventions. Further studies will be required to establish whether patients with hypoalbuminemia would benefit from administration of gastro-protectant medications.

Gastro-protectant medications were administered to a large proportion of the animals included in this study, which complicated the interpretation of the results obtained, particularly because animals that ultimately developed SRMD were more likely to have received one or more of these products. This variable was included when fitting the logistic regression model due to its \textit{a priori} importance\textsuperscript{2}, but it
would have been preferable to evaluate groups of treated and untreated dogs separately in a stratified model\textsuperscript{23}. This approach was not attempted in this study as the number of cases in each subgroup would have been insufficient to evaluate the number of risk factors included.

Univariable analysis identified several other factors that were significantly associated with development of SRMD, including several that have previously been associated with the analogous disease in humans, such as hepatopathy, nephropathy and thrombocytopenia. Cook and colleagues\textsuperscript{2} reported hepatic and renal failure as significant risk factors for development of clinically important bleeding after univariable analysis, but only secondary coagulopathy and respiratory failure necessitating mechanical ventilation were retained in the multivariable model. Failure to identify these variables as risk factors for SRMD in this study probably relates to the relatively low prevalence of these problems in this sample, and in veterinary ICU caseloads in the UK.

SRMD and placement of a feeding tube were significantly more likely to occur in dogs that died or were euthanized compared to those that were discharged. Placement of a feeding tube is considered to be a relatively benign procedure\textsuperscript{24} and, in this group of patients, was usually performed at the same time as imaging or other procedures that necessitated general anesthesia or sedation. Placement of a feeding tube in this model is more likely to be a proxy variable that could represent a prolonged history of anorexia or anticipated anorexia, or a patient likely to require a long period of intensive care following placement. Feeding tubes were also placed in four patients in preparation for mechanical ventilation, which is also likely to be a poor prognostic indicator in veterinary ICU patients\textsuperscript{25}. The authors do not consider that use of a feeding tube \textit{per se} should increase the risk of death as this procedure is usually well tolerated or is associated with only minor complications\textsuperscript{24}. Procedures are also employed at all three centers to minimize the risk of refeeding syndrome in dogs with prolonged anorexia.
Evidence from human medicine suggests that enteral nutrition should be beneficial for patients with stress-related GI disease, and early re-introduction of enteral feeding may reduce the requirement for gastro-protectant medications. A recent pilot study of dogs with pancreatitis further indicated that enteral feeding was well tolerated in critical care patients and was not associated with a greater prevalence of adverse effects compared to administration of parenteral nutrition, and a study of dogs with septic peritonitis suggested that introduction of early enteral nutrition was associated with shorter duration of hospitalization. Nevertheless, it remains to be determined in future studies whether re-introduction of enteral nutrition would prevent the hemorrhagic GI disease reported in patients in this study.

Development of hemorrhagic GI disease in patients that did not present for investigation or management of GI disease is likely to cause increased morbidity, either due to development of anemia, production and release of further inflammatory mediators, or increased risk of bacterial translocation across the wall of the stomach or upper small intestine. SRMD may itself act as a proxy variable for severe systemic disease, such as SIRS, sepsis, or multiple organ dysfunction syndrome (MODS). A variable describing fulfilment of established SIRS criteria was included in the final model of factors associated with mortality during hospitalization to try to account for this possibility as this factor was shown to be significant in a previous study. Despite this, development of SRMD remained an independent predictor of mortality, and the higher risk of mortality among patients that developed SRMD is consistent with findings in humans with overt clinical hemorrhage due to GI disease.

Limitations: Limitations of this study include the relatively small number of cases included, especially for investigation of risk factors for development of SRMD and mortality. Animals with SRMD were more likely to have been hospitalized at Centers 1 and 2 than Center 3, and, although institution was included as an independent factor in all multivariable analyses, it is possible that unmeasured differences between centers could have acted as confounding or modifying factors.
Although much of the data included in this study was collected prospectively, some information regarding development of GI disease was collected retrospectively from clinical records, reducing the reliability and consistency of these findings. Data were also collected by a number of different investigators who may not have been involved in the primary care of the case.

**Conclusions:** SRMD was observed in dogs from three different veterinary ICUs but was not observed in cats. Decreased serum albumin concentration was associated with development of SRMD, but, using a clinically relevant cut off value, this variable had a poor sensitivity and specificity for prediction of the disease. Development of SRMD and placement of a feeding tube were independently associated with increased mortality while hospitalized, but further studies will be required to determine the effects and potential benefits of prophylactic gastro-protectant therapy in veterinary ICU patients.

**Footnotes**


**References**


Figure 1: Flow diagram of cases included in study

Supplementary Figure 1: Receiver operator characteristic curves generated using (A) probabilities from the multivariable regression model of risk factors for development of SRMD and (B) serum concentrations of albumin

Supplementary Figure 2: Receiver operator characteristic curve generated using probabilities derived from multivariable logistic regression model of risk factors for mortality during hospitalization